Company intelligence / Profile preview
Neurocentria Inc.
Walnut Creek, North Carolina, United Statesneurocentria.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Neurocentria has received FDA approval for pivotal Phase 2b/3 trials for NRCT-101SR in adults with ADHD. Early-stage clinical trials showed the drug addresses ADHD symptoms without side effects, improves mood status in 3-7 days, improves cognition, and produces no reported adverse side effects relative to placebo. The company also has approval for Phase 2b trials for Alzheimer's disease and is seeking approval for Phase 2b/3 trials for late-life depression.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Neurocentria Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurocentria Inc..